Education
About Us
Working with TipRanks
Follow Us
Ultragenyx Pharmaceutical (RARE)
NASDAQ:RARE
RARE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$30.46 - $60.37
Previous CloseN/A
Volume75.38K
Average Volume (3M)752.84K
Market Cap
$3.05B
Enterprise Value$4.33B
Total Cash (Recent Filing)-$86.19M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.21
Next Earnings
May 01, 2025EPS Estimate
-1.57Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.34
Shares Outstanding93,899,666
10 Day Avg. Volume750,740
30 Day Avg. Volume752,836
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.47
Price to Cash Flow (P/CF)-11.40
P/FCF Ratio0.00
Enterprise Value/Market Cap1.42
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit8.95
Enterprise Value/Ebitda-9.22
Forecast
1Y Price Target
$91.00Price Target Upside183.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceUltragenyx provided a strong revenue growth guidance with expected 17% year-over-year growth at the midpoint for FY25.
Product LaunchUX111 could be Ultragenyx's first gene therapy launch, setting the stage for several other programs in the pipeline.
Regulatory MilestoneThe FDA has accepted the BLA of UX111 for Priority Review under an accelerated approval pathway, indicating a significant regulatory milestone for Ultragenyx.
Bears Say
Clinical Trial UncertaintyThere is a focus on the second interim analysis for setrusumab in mid-2025, while the pipeline continues to progress nicely.
Commercial VariabilityThere is a reiterated Buy rating with a price objective of $83, indicating confidence in the stock's future performance.
Investment RisksThere are risks to the investment thesis, including potential clinical trial failures, failure to secure regulatory approvals, and smaller than anticipated commercial opportunities.
---
Ownership Overview
4.14% Insiders
29.07% Mutual Funds
35.83% Other Institutional Investors
17.21% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RARE FAQ
What was Ultragenyx Pharmaceutical’s price range in the past 12 months?
Ultragenyx Pharmaceutical lowest stock price was $30.46 and its highest was $60.37 in the past 12 months.
What is Ultragenyx Pharmaceutical’s market cap?
Ultragenyx Pharmaceutical’s market cap is $3.05B.
When is Ultragenyx Pharmaceutical’s upcoming earnings report date?
Ultragenyx Pharmaceutical’s upcoming earnings report date is May 01, 2025 which is in 22 days.
How were Ultragenyx Pharmaceutical’s earnings last quarter?
Ultragenyx Pharmaceutical released its earnings results on Feb 13, 2025. The company reported -$1.39 earnings per share for the quarter, missing the consensus estimate of -$1.308 by -$0.082.
Is Ultragenyx Pharmaceutical overvalued?
According to Wall Street analysts Ultragenyx Pharmaceutical’s price is currently Undervalued.
Does Ultragenyx Pharmaceutical pay dividends?
Ultragenyx Pharmaceutical does not currently pay dividends.
What is Ultragenyx Pharmaceutical’s EPS estimate?
Ultragenyx Pharmaceutical’s EPS estimate is -1.57.
How many shares outstanding does Ultragenyx Pharmaceutical have?
Ultragenyx Pharmaceutical has 93,899,666 shares outstanding.
What happened to Ultragenyx Pharmaceutical’s price movement after its last earnings report?
Ultragenyx Pharmaceutical reported an EPS of -$1.39 in its last earnings report, missing expectations of -$1.308. Following the earnings report the stock price went down -2.367%.
Which hedge fund is a major shareholder of Ultragenyx Pharmaceutical?
Currently, no hedge funds are holding shares in RARE
---
Ultragenyx Pharmaceutical Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$91.00 (183.14% Upside)
$91.00 (183.14% Upside)
Blogger Sentiment
Bullish
RARE Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 491.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $5.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.7%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-36.02%
12-Months-Change
Fundamentals
Return on Equity
-214.50%
Trailing 12-Months
Asset Growth
0.43%
Trailing 12-Months
Company Description
Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
---
RARE Company Deck
---
RARE Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected strong revenue growth and successful international expansion, alongside notable advancements in clinical programs. However, significant net losses and high operating expenses present financial challenges. The positive highlights slightly outweigh the concerns, indicating a cautiously optimistic outlook.Read More>---
RARE Stock 12 Month Forecast
Average Price Target
$91.00
▲(183.14% Upside)
Technical Analysis
Amicus
―
BioMarin Pharmaceutical
―
Vertex Pharmaceuticals
―
Sarepta Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering RARE
1 Year
1 Year Success Rate
7/17 ratings generated profit
1 Year Average Return
+5.85%
reiterated a buy rating 6 days ago
Copying Joon Lee's trades and holding each position for 1 Year would result in 41.18% of your transactions generating a profit, with an average return of +5.85% per trade.
---